Pharma industry trade group PhRMA generally protects its own amid controversy. But now, it’s put up a statement on its website criticizing a drugmaker that’s surrounded by plenty.
Thursday, the group likened the Canadian drugmaker Valeant Pharmaceuticals to much-maligned Turing Pharmaceuticals, noting that its strategy is “more reflective of a hedge fund than an innovative biopharmaceutical company.”
Unlike Valeant, the innovators “have R&D at the core–and the numbers to prove it,” the post says. The Quebec-based pharma, on the other hand, has made its way by serially acquiring companies and squeezing out costs, investing on average less than 3% of its total revenue on R&D.
It’s the latest effort by the group to distance itself from the drug price uproar coming from lawmakers, presidential candidates and–in the case of Valeant–federal prosecutors. Earlier this week, short seller Citron Research likened Valeant to Enron and claimed it used its relationship with specialty pharmacies to inflate its top line; that relationship was one of the subjects of a pair of federal subpoenas the company last week announced it had received.
Turing, which drew ire when it last month hiked the price of Daraprim by more than 5000%, felt a similar burn from the trade organization when PhRMA put out a tweet stating that the company didn’t represent the values of its member companies.
Meanwhile, Valeant said Monday that it’s looking to sock more money into R&D. It’ll also look to hive off its neurology and “other drugs” unit, which has been subject to some of its biggest price hikes, and it’ll pursue fewer–if any–transactions “focused on mispriced products,” CEO J. Michael Pearson said on a conference call.
But those assurances didn’t do much to sooth investors’ worries when Citron’s “phantom sales” allegations hit. After plunging 19% Wednesday, Valeant’s share price dropped another 7.4%, Bloomberg points out, with one BMO Capital Markets analyst downgrading the stock.
By Carly Helfand
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
